Quantum BioPharma anticipates funding to extend past March 2027.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Should l Buy QNTM?
Financial Position: Quantum BioPharma reported a stronger financial position at the end of Q3 2025, with reduced liabilities, increased shareholder equity, and ongoing efficiencies, alongside a robust product pipeline targeting brain disorders and alcohol health.
Unbuzzd Wellness Financing: Unbuzzd Wellness has initiated a Reg D financing for up to $5M to support a potential public transaction, which will allow Quantum to monetize its holdings without dilution.
Product License and MS Program: Health Canada granted a Product License for Qlarity, a natural health product, while Quantum's partnership with Massachusetts General Hospital is advancing in the MS program, with promising results from the Lucid-MS compound.
Cryptocurrency Strategy: Quantum continues to manage its treasury risk through cryptocurrency investments, reporting significant profits of $572,000, primarily from Bitcoin, and aims to maintain a strong financial position beyond March 2027.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QNTM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QNTM
About QNTM
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quantum Biopharma Investors Class Action Notice
- Class Action Notice: Quantum Biopharma, Ltd. is facing a class action lawsuit for securities transactions between January 6, 2021, and October 15, 2025, with investors required to file a lead plaintiff motion by February 23, 2026, to protect their legal rights.
- False Trading Allegations: The complaint alleges that defendants engaged in thousands of spoofed sell orders during the class period, creating a false appearance of declining stock prices, which led investors to sell their shares at artificially depressed prices, resulting in improper losses.
- Market Manipulation: Defendants profited from the scheme by purchasing Quantum shares at artificially deflated levels after driving the market price down, demonstrating misconduct that improperly induced investors to sell their shares.
- Legal Assistance Offered: The Portnoy Law Firm provides complimentary case evaluations for affected investors, emphasizing their commitment to helping recover losses caused by corporate wrongdoing and protecting investor rights.
See More
Quantum Biopharma Class Action Notice for Investors
- Class Action Notice: The Portnoy Law Firm advises Quantum Biopharma Ltd. (NASDAQ: QNTM) investors of a class action for those who purchased securities between January 6, 2021, and October 15, 2025, with a deadline of February 23, 2026, for filing a lead plaintiff motion, indicating significant legal risks for the company.
- False Statement Allegations: The complaint alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose their manipulation through thousands of spoofed sell orders, creating a false appearance of declining stock prices, highlighting severe market manipulation issues.
- Investor Losses: As a result of the defendants' misconduct, investors were improperly induced to sell their shares at artificially depressed prices, leading to significant financial losses, which reflects a lack of corporate governance and transparency that could undermine future investor confidence.
- Legal Consultation Opportunity: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to contact attorneys to discuss their legal rights, indicating the potential liability of the company regarding legal issues and the necessity for investor advocacy.
See More
CIBC and RBC Accused of Manipulating Quantum Stock Prices
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC), alleging that they defrauded investors by manipulating trades that artificially deflated the price of Quantum Biopharma Ltd. (NASDAQ: QNTM) stock.
- Manipulative Trading Practices: The complaint alleges that throughout the class period, the defendants repeatedly placed thousands of spoofed sell orders, creating a false impression of declining stock prices, which deceived investors into selling their shares at artificially depressed prices, allowing the defendants to profit from the scheme.
- Investor Losses: As a result of the defendants' misconduct, investors were improperly induced to sell their Quantum shares at lower than market value, with the lawsuit seeking damages on behalf of all individuals who sold Quantum securities between January 6, 2021, and October 15, 2025.
- No Cost for Investors: Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees from the court if they are successful in recovering losses, allowing investors to participate in the lawsuit without financial risk.
See More
CIBC and RBC Accused of Manipulating Quantum Stock Prices
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC), alleging that they defrauded investors by manipulating trades to artificially depress the stock price of Quantum Biopharma Ltd. (NASDAQ: QNTM).
- Manipulative Trading Allegations: The complaint claims that from January 6, 2021, to October 15, 2025, the defendants placed thousands of spoofed sell orders, creating a false impression of declining stock prices, which deceived investors into selling their shares at artificially low prices.
- Investor Losses: As a result of the defendants' actions, investors were improperly induced to sell Quantum shares at depressed prices, and the lawsuit seeks to recover damages for all individuals who sold Quantum securities during the class period.
- No Cost for Investors: Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees if they successfully recover losses, thereby minimizing financial risk for investors.
See More
CIBC and RBC Accused of Manipulating Quantum Stock Prices
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC), alleging that they defrauded investors by manipulating trades to artificially depress the stock price of Quantum Biopharma Ltd. (NASDAQ: QNTM).
- Manipulative Trading Allegations: The complaint claims that from January 6, 2021, to October 15, 2025, the defendants placed thousands of spoofed sell orders, creating a false impression of declining stock prices, which misled investors into selling their shares at artificially low prices.
- Investor Losses: As a result of the defendants' actions, investors were improperly induced to sell their shares at depressed prices, and the lawsuit seeks to recover damages for all individuals who sold Quantum securities during the class period.
- Contingency Fee Arrangement: Bronstein, Gewirtz & Grossman LLC represents investors on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees if they successfully recover funds, thereby minimizing the financial risk for investors.
See More
Quantum Biopharma Ltd. Class Action Notice for Investors
- Class Action Notice: Quantum Biopharma Ltd. is facing a class action lawsuit for securities transactions between January 6, 2021, and October 15, 2025, with investors required to file a lead plaintiff motion by February 23, 2026, indicating significant legal risks that may undermine shareholder confidence.
- False Trading Allegations: The lawsuit alleges that the company engaged in thousands of spoofed sell orders during the class period, intentionally creating a false appearance of declining stock prices, which led investors to sell their shares at artificially depressed prices, highlighting severe governance issues within the company.
- Investor Losses: As a result of the defendants' actions, investors were improperly induced to sell their shares at artificially low prices, resulting in undue losses, which suggests potential misconduct in market manipulation that could lead to broader legal repercussions.
- Legal Consultation Opportunity: Investors can obtain a complimentary case evaluation from the Portnoy Law Firm, indicating that the firm is actively providing legal support for affected investors, which may influence future investor confidence and market performance.
See More
Quantum Biopharma Investors Class Action Notice
- Class Action Notice: Quantum Biopharma, Ltd. is facing a class action lawsuit for securities transactions between January 6, 2021, and October 15, 2025, with investors required to file a lead plaintiff motion by February 23, 2026, to protect their legal rights.
- False Trading Allegations: The complaint alleges that defendants engaged in thousands of spoofed sell orders during the class period, creating a false appearance of declining stock prices, which led investors to sell their shares at artificially depressed prices, resulting in improper losses.
- Market Manipulation: Defendants profited from the scheme by purchasing Quantum shares at artificially deflated levels after driving the market price down, demonstrating misconduct that improperly induced investors to sell their shares.
- Legal Assistance Offered: The Portnoy Law Firm provides complimentary case evaluations for affected investors, emphasizing their commitment to helping recover losses caused by corporate wrongdoing and protecting investor rights.
See More
Quantum Biopharma Class Action Notice for Investors
- Class Action Notice: The Portnoy Law Firm advises Quantum Biopharma Ltd. (NASDAQ: QNTM) investors of a class action for those who purchased securities between January 6, 2021, and October 15, 2025, with a deadline of February 23, 2026, for filing a lead plaintiff motion, indicating significant legal risks for the company.
- False Statement Allegations: The complaint alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose their manipulation through thousands of spoofed sell orders, creating a false appearance of declining stock prices, highlighting severe market manipulation issues.
- Investor Losses: As a result of the defendants' misconduct, investors were improperly induced to sell their shares at artificially depressed prices, leading to significant financial losses, which reflects a lack of corporate governance and transparency that could undermine future investor confidence.
- Legal Consultation Opportunity: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to contact attorneys to discuss their legal rights, indicating the potential liability of the company regarding legal issues and the necessity for investor advocacy.
See More
CIBC and RBC Accused of Manipulating Quantum Stock Prices
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC), alleging that they defrauded investors by manipulating trades that artificially deflated the price of Quantum Biopharma Ltd. (NASDAQ: QNTM) stock.
- Manipulative Trading Practices: The complaint alleges that throughout the class period, the defendants repeatedly placed thousands of spoofed sell orders, creating a false impression of declining stock prices, which deceived investors into selling their shares at artificially depressed prices, allowing the defendants to profit from the scheme.
- Investor Losses: As a result of the defendants' misconduct, investors were improperly induced to sell their Quantum shares at lower than market value, with the lawsuit seeking damages on behalf of all individuals who sold Quantum securities between January 6, 2021, and October 15, 2025.
- No Cost for Investors: Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees from the court if they are successful in recovering losses, allowing investors to participate in the lawsuit without financial risk.
See More
CIBC and RBC Accused of Manipulating Quantum Stock Prices
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC), alleging that they defrauded investors by manipulating trades to artificially depress the stock price of Quantum Biopharma Ltd. (NASDAQ: QNTM).
- Manipulative Trading Allegations: The complaint claims that from January 6, 2021, to October 15, 2025, the defendants placed thousands of spoofed sell orders, creating a false impression of declining stock prices, which deceived investors into selling their shares at artificially low prices.
- Investor Losses: As a result of the defendants' actions, investors were improperly induced to sell Quantum shares at depressed prices, and the lawsuit seeks to recover damages for all individuals who sold Quantum securities during the class period.
- No Cost for Investors: Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees if they successfully recover losses, thereby minimizing financial risk for investors.
See More
CIBC and RBC Accused of Manipulating Quantum Stock Prices
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC), alleging that they defrauded investors by manipulating trades to artificially depress the stock price of Quantum Biopharma Ltd. (NASDAQ: QNTM).
- Manipulative Trading Allegations: The complaint claims that from January 6, 2021, to October 15, 2025, the defendants placed thousands of spoofed sell orders, creating a false impression of declining stock prices, which misled investors into selling their shares at artificially low prices.
- Investor Losses: As a result of the defendants' actions, investors were improperly induced to sell their shares at depressed prices, and the lawsuit seeks to recover damages for all individuals who sold Quantum securities during the class period.
- Contingency Fee Arrangement: Bronstein, Gewirtz & Grossman LLC represents investors on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees if they successfully recover funds, thereby minimizing the financial risk for investors.
See More
Quantum Biopharma Ltd. Class Action Notice for Investors
- Class Action Notice: Quantum Biopharma Ltd. is facing a class action lawsuit for securities transactions between January 6, 2021, and October 15, 2025, with investors required to file a lead plaintiff motion by February 23, 2026, indicating significant legal risks that may undermine shareholder confidence.
- False Trading Allegations: The lawsuit alleges that the company engaged in thousands of spoofed sell orders during the class period, intentionally creating a false appearance of declining stock prices, which led investors to sell their shares at artificially depressed prices, highlighting severe governance issues within the company.
- Investor Losses: As a result of the defendants' actions, investors were improperly induced to sell their shares at artificially low prices, resulting in undue losses, which suggests potential misconduct in market manipulation that could lead to broader legal repercussions.
- Legal Consultation Opportunity: Investors can obtain a complimentary case evaluation from the Portnoy Law Firm, indicating that the firm is actively providing legal support for affected investors, which may influence future investor confidence and market performance.
See More
